Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1952 1
1954 1
1955 2
1956 2
1957 3
1958 2
1959 2
1960 4
1961 2
1962 4
1963 10
1964 5
1965 8
1966 13
1967 11
1968 15
1969 16
1970 11
1971 20
1972 19
1973 19
1974 21
1975 12
1976 24
1977 17
1978 28
1979 25
1980 24
1981 41
1982 42
1983 58
1984 57
1985 61
1986 59
1987 64
1988 69
1989 80
1990 85
1991 74
1992 69
1993 79
1994 93
1995 104
1996 124
1997 113
1998 112
1999 130
2000 115
2001 125
2002 134
2003 145
2004 119
2005 141
2006 132
2007 128
2008 143
2009 141
2010 168
2011 166
2012 175
2013 183
2014 172
2015 190
2016 218
2017 223
2018 212
2019 211
2020 221
2021 265
2022 244
2023 211
2024 236
2025 234
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,932 results

Results by year

Filters applied: . Clear all
Page 1
Medication Optimization Protocol Efficacy for Geriatric Inpatients: A Randomized Clinical Trial.
Ie K, Hirose M, Sakai T, Motohashi I, Aihara M, Otsuki T, Tsuboya A, Matsumoto H, Hashi H, Inoue E, Takahashi M, Komiya E, Itoh Y, Machino R, Tsuchida T, Albert SM, Ohira Y, Okuse C. Ie K, et al. Among authors: sakai t. JAMA Netw Open. 2024 Jul 1;7(7):e2423544. doi: 10.1001/jamanetworkopen.2024.23544. JAMA Netw Open. 2024. PMID: 39078632 Free PMC article. Clinical Trial.
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, Hirai S, Nakamura R, Morimoto K, Furuya N, Arai S, Goto Y, Sakata Y, Nishino K, Tsuchiya M, Tamiya A, Saito G, Muto S, Takeda T, Date K, Fujisaka Y, Watanabe S, Fujimoto D, Uehara H, Horinaka M, Sakai T, Yano S, Tokuda S, Takayama K. Katayama Y, et al. Among authors: sakai t. Clin Cancer Res. 2025 Mar 17;31(6):1127-1141. doi: 10.1158/1078-0432.CCR-24-1762. Clin Cancer Res. 2025. PMID: 39495173
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Kato Y, Udagawa H, Matsumoto S, Izumi H, Ohe Y, Kato T, Nishino K, Miyamoto S, Kawana S, Chikamori K, Shingyoji M, Sato Y, Takada Y, Toyozawa R, Azuma K, Tanaka Y, Sakai T, Shibata Y, Sugiyama E, Nosaki K, Zenke Y, Umemura S, Yoh K, Seike M, Goto K. Kato Y, et al. Among authors: sakai t. Lung Cancer. 2024 Nov;197:107992. doi: 10.1016/j.lungcan.2024.107992. Epub 2024 Oct 13. Lung Cancer. 2024. PMID: 39423763
Trametinib Suppresses the Stimulated T Cells Through G1 Arrest and Apoptosis.
Nakao T, Shindo T, Takakura H, Narita T, Ise-Nakao Y, Akiyama S, Iizumi Y, Boku S, Watanabe M, Sakai T, Shimizu S, Yamada M, Sowa Y, Mutoh M. Nakao T, et al. Among authors: sakai t. Eur J Immunol. 2025 Feb;55(2):e202350667. doi: 10.1002/eji.202350667. Eur J Immunol. 2025. PMID: 39989249
NETosis in pulmonary pleomorphic carcinoma.
Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. Oi H, et al. Among authors: sakai t. Cancer Sci. 2025 Feb;116(2):524-532. doi: 10.1111/cas.16332. Epub 2024 Nov 18. Cancer Sci. 2025. PMID: 39555736 Free PMC article.
Ovarian Follicle Development in Ascidians.
Satake H, Kawada T, Osugi T, Sakai T, Shiraishi A, Yamamoto T, Matsubara S. Satake H, et al. Among authors: sakai t. Zoolog Sci. 2024 Feb;41(1):60-67. doi: 10.2108/zs230054. Zoolog Sci. 2024. PMID: 38587518 Review.
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, Hirai S, Ishida M, Kawachi H, Sawada R, Tachibana Y, Osoegawa A, Horinaka M, Sakai T, Yasuhiro T, Kozaki R, Yano S, Takayama K. Nakamura R, et al. Among authors: sakai t. Cancer Lett. 2024 Aug 28;598:217124. doi: 10.1016/j.canlet.2024.217124. Epub 2024 Jul 24. Cancer Lett. 2024. PMID: 39059573 Free article.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, Tachibana Y, Matsui Y, Nakamura R, Ishida M, Kawachi H, Kunimasa K, Sasaki T, Nishida M, Furuya N, Watanabe S, Shiotsu S, Nishioka N, Horinaka M, Sakai T, Uehara H, Yano S, Son BK, Tokuda S, Takayama K. Morimoto K, et al. Among authors: sakai t. Cancer Lett. 2024 Apr 10;587:216692. doi: 10.1016/j.canlet.2024.216692. Epub 2024 Feb 9. Cancer Lett. 2024. PMID: 38342232 Free article.
5,932 results